When Rare Is Not Small: Amyotrophic Lateral Sclerosis Initiatives and Therapy

In the precision-medicine era, rare diseases must not be sidelined in translational infrastructure. The Mr. Cai Lei—led “Ice-Breaking Team” turns an amyotrophic lateral sclerosis patient community into a sustainable ecosystem, realigning philanthropy, data, and research and development to reshape rare-disease pipelines and guide precision therapies, offering a replicable blueprint for rare-disease strategies. Rare diseases, though individually uncommon, collectively affect millions of people worldwide, constituting a substantial yet often underserved patient population. Owing to their low prevalence per condition, rare diseases frequently fall outside the strategic priorities of major pharmaceutical companies, limiting the pace and scope of therapeutic development. At the same time, personalized medicine is becoming the norm, enabled by genomics, biomarkers, and targeted delivery. If we can tailor therapies to subgroups of common diseases, the same logic has no reason not to apply to rare diseases. The challenge extends beyond scientific innovation, but structural barriers: fragmented patients, scarce funding, and weak incentives. Our discussion draws on the model pioneered by Mr. Cai Lei and the Ice-Breaking Team in China, who combined philanthropy, public engagement, and an open laboratory network to accelerate translational research for amyotrophic lateral sclerosis (ALS). Their approach highlights how new funding mechanisms, public awareness and cross-sector collaboration could reshape the rare disease research and development (R&D) landscape. Ultimately, solving rare diseases requires building a sustainable ecosystem, one that balances ethics with access, protects innovation while ensuring affordability, and fosters a scientific common that turns limited resources into an “infinite arsenal” against disease. Rare diseases, each affecting a small number of individuals, collectively impact more than 300 million people worldwide [1, 2]. This burden, comparable in magnitude to many common diseases, demonstrates that the global burden of rare conditions is far from marginal (Figure 1). Despite this, therapeutic development for rare diseases remains disproportionately underfunded and underprioritized. The core challenge lies in their fragmented prevalence: most rare diseases affect fewer than 1 in 2000 people, and many impact just a handful of individuals worldwide [3, 4]. This epidemiological reality leads to limited commercial incentives, especially under traditional drug development models where return on investment is tightly coupled to patient volume. Consequently, rare disease therapies have historically relied on targeted public funding, orphan drug legislation, or philanthropic efforts to progress [5]. Large pharmaceutical companies may engage in rare disease programs where platform technologies (e.g., antisense oligonucleotides, AAV vectors) can be reused, but they tend to concentrate their resources on diseases with broader market potential. This strategic calculus has reinforced a structural inequity: patients with rare diseases often face not only a lack of effective treatments, but also delayed diagnoses, clinical trial inaccessibility, geographic variations, and limited post-market care options. Reflecting this urgency, the World Health Organization (WHO) has recently elevated rare diseases to a global health priority, urging member states to embed them within their national health plans, expand equitable access to diagnosis and treatment, including universal newborn screening, and commit to a 10-year global action plan that coordinates research, policy, and care worldwide [6]. In line with this global agenda, multiple policy frameworks now support rare disease research and therapeutic translation. Many countries have established orphan-drug incentives and flexible approval pathways, and comprehensive overviews of national landscapes can be accessed through platforms such as Rare Diseases International (RDI) Resource Maps and the International Rare Diseases Research Consortium (IRDiRC) Policies and Guidelines, while specific regulatory details can be found on each country's official agency websites. In parallel, the rise of personalized medicine has transformed our understanding of disease heterogeneity and therapeutic response [7]. Driven by advances in genomics, transcriptomics, and biomarker discovery, the concept of “one-size-fits-all” medicine is giving way to tailored treatment strategies, even within diseases previously considered homogeneous. Oncology and immunology, for example, have embraced molecular subtyping to guide therapy selection, enabling more precise and effective interventions [8]. However, while personalized medicine shares philosophical alignment with rare disease treatment, both aim to address unique molecular profiles, the translational infrastructure supporting rare diseases has not advanced at the same pace. In practice, the individualized nature of rare diseases has not yet translated into equitable therapeutic development. Instead of enabling innovation, rarity often remains a barrier due to high per-patient development costs, regulatory complexity, and insufficient longitudinal data to support traditional drug approval frameworks. This disconnect highlights the urgent need for foundational technological and systemic innovations. Platform technologies, such as modular gene editing systems [9], programmable RNA drugs [10], synthetic biology circuits [11], or nanoparticle-based delivery systems [12], offer the potential to generate reusable, scalable therapeutic solutions. At the same time, harmonizing regulatory pathways, enabling adaptive trial designs, and embedding patient registries into research pipelines can reduce both risk and cost. If implemented strategically, these advances can help shift the focus from rarity as a limitation to rarity as an opportunity for innovation, allowing the field to sustainably deliver therapies that are both clinically impactful and economically viable. Gene therapy has emerged as a key strategy for rare disease treatment, particularly for monogenic disorders [5]. While viral vectors, especially adeno-associated viruses (AAVs), have driven early clinical successes (Zolgensma, Luxturna), the field is now facing a strategic turning point. Several leading pharmaceutical companies have recently scaled back or terminated AAV-based programs, citing challenges including immune toxicity, limited tissue penetration, high manufacturing costs, and uncertain long-term outcomes. This withdrawal reflects deeper structural issues. AAV delivery to the central nervous system (CNS) often requires high systemic doses, increasing the risk of hepatotoxicity and immune responses. Re-dosing is complicated by the development of neutralizing antibodies, and achieving consistent biodistribution, especially in heterogeneous tissues like the brain, remains technically difficult. For rare diseases, the economic return on investment is often insufficient to justify these risks, even with orphan drug incentives. Furthermore, some high-profile failures in late-stage trials have shaken investor and regulatory confidence, leading companies to reprioritize toward broader or lower-risk pipelines. Genetic background heterogeneity and cellular-level variability in disease lesions demand a truly integrative approach to target identification, one that harnesses artificial intelligence (AI)-powered imaging, pathological biomarkers, and multi-omics spanning the transcriptome, proteome, metabolome, epigenome, and even environmental “exposome” data. This convergence with AI opens the door to building virtual cells, computationally modeled simulation systems that could revolutionize hypothesis testing and drug discovery. These AI-driven frameworks can also condense heterogeneous patient-level information into evolving, clinically meaningful digital phenotypes, providing a generative synopsis of multi-source data for target prioritization, risk stratification, and trial design. We are witnessing a rapid expansion of innovative therapeutic modalities, ranging from single-molecule constructs to and to designs, including tissue solutions. However, these remains a models often fall of while and systems lack in such as and that disease the delivery both viral and to especially and of for are a through that and of them as in gene in and manufacturing are to truly personalized for rare diseases a reality (Figure we the and of viral neutralizing with low especially for regulatory and trial are to support can manufacturing be more flexible and multiple gene therapy platforms offer delivery and to viral in these both scientific innovation and structural also the need to development models that can while a focus on patient an where such as by an patient and Mr. Cai offer In the face of and translational challenges in rare disease have to reshape the research and development landscape. the most is the of Mr. Cai an and of the “Ice-Breaking a (Figure that to accelerate therapeutic and for and diseases and rare diseases. The Ice-Breaking approach is by of patient scientific and translational infrastructure. to this is the a that has into the patient This platform not only as a data but also as a clinical enabling patient stratification, rapid trial and how patient can to the translational the Ice-Breaking model is collaboration The research through global and and targeted with clinical and than funding research, the in and within and clinical This the and therapeutic development under the Ice-Breaking a This model has the development of therapies, including a now in clinical has also how funding from philanthropic to investment can for traditional or pharmaceutical in the of development. scientific with urgency, the Ice-Breaking Team a blueprint for rare disease than for engagement, this model translational the and commercial in a and address the that patients, and care the Team an with Cai Mr. Cai is a with and the of the Ice-Breaking and the Platform in of the Ice-Breaking with Mr. and of from to to public engagement, and patient the support of from the and Ice-Breaking they and from Mr. leading this patients most limited to for example, need with more common diseases, are the in the Mr. Cai Lei and Ice-Breaking is a rare disease. In China, the is per with patients patients face and the to and even is just to is often as of the Despite of the remains therapeutic are and no treatment can the disease. The is For patients, the most urgent need is a in drug therapies that can or disease or even a This is also the our to However, while for such patients not only but also to some Our of the is a community that patients a platform to and At the same time, we within the patient community to and effective patients often fall into and to support We are with the Health to this for example, by with for patients and their and by These efforts help patients one and their and in facing the disease. in research For rare diseases such as the pathological may multiple including and immune system but how these and disease and is This to effective therapeutic and drug development research patient are clinical as patient tissue especially and and biomarker are these are and to them for This deeper and more comprehensive of the disease. funding commercial The market for rare disease drugs is a commercial pharmaceutical companies often to in diseases with broader patient and For rare diseases such as a new drug high and high but limited investment and a funding for drug research and philanthropic some funding, the to rare disease research remains than that for common diseases. This is far from to support comprehensive research from to clinical challenges in clinical trials trials of patients to the and of However, the small patient to at the of leading to trial progress or even trial drug development trial Rare disease patients often and of This to and drug in In the of many patients and and on the scientific and of of resources of The number of who are in rare disease treatment, and long-term is Many lack may to or in providing comprehensive and treatment and treatment of rare diseases and At collaboration with information and limited to deliver comprehensive and can progress in In of patient scientific research, and has the of an or Mr. Cai Lei and Ice-Breaking and rare diseases requires and pharmaceutical companies with the the of has In with the support and of we global scientific with more than and their as as research and of these have advanced to a deeper the research we have with such as from the of an research and of at to new in drug development and therapeutic strategies. In of we have with patient such as one of the most comprehensive research to from their in and patient We have also with and patients to that global For example, in Mr. Cai with Mr. of the and the the a spanning The aim to more and people from of to to patients and the of treatments, increasing the of through global in and has regulatory and for clinical trial approval and drug This the and of and drug development. to data in research data research requires clinical and data, yet many countries on data to and in are by national the one efforts may face due to and affecting and the are to regulatory for and collaboration from on the of these In are the core in research from the to the patient drug or clinical trial In of and long-term the most Mr. Cai Lei and Ice-Breaking In the drug delivery and clinical trial the most with some into disease mechanisms, achieving effective drug delivery to remains a major particularly the need to the is for At the same time, clinical trial to patient For example, patient is often leading to therapeutic by the only this are and may only apply to patient but trial such The lack of this advanced delivery technologies (e.g., nanoparticle-based and as to trial and the of therapeutic In the the central lies in the understanding of is to patient from including (e.g., (e.g., and However, a pathological model remains to in of disease and research lack in a fragmented understanding of core a rare challenges in Many drug that in models have in clinical trials due to and from in but the rarity and variability of the even more substantial investment in research and the of multi-omics (e.g., genomics, to disease In the the lies in the economic and policy rare disease drug development. face the high and risk of development with limited market This pharmaceutical incentives and the of research due to funding and translational this requires systemic policy such as for clinical research (e.g., approval offering incentives, or providing research to investment in rare disease The a example, market and support to rare disease drug development. the progress on platforms (e.g., and that AI-driven with long-term patient frameworks can address the and heterogeneity of and a and with the strategy of patients, mechanisms, and long-term a each be by funding is and can support be to rare disease research and treatment, for example, through and through national research Mr. Cai Lei and Ice-Breaking Our this This not on a funding one for is key to patient access and affordability, public and the for drugs not yet but clinical models an the trial patient and in patient and in companies, and for treatment with patient care on multiple and innovative innovation is also and gene therapies are the most for rare diseases. The International in has as a national for health policy, a regulatory to accelerate the of advanced the on in the of a new is for clinical in the must with health and for public This protects to and public with innovation pathways, this has the of translational and we such can be that more patients can access therapies like and gene while the development of The is national research programs can guide scientific to focus on rare disease mechanisms, such as the molecular of disease and and the of therapeutic This is to the that progress and the for a requires commercial has the to and therapies to the of and translational are in commercial investment can accelerate drug and ensuring sustainable The of can a enabling can reduce on and access to research funding, can where market incentives are ensuring resources are to key rare disease can incentives, and policy frameworks that by pharmaceutical companies, research and This a that and long-term toward the of rare diseases. medicine is a concept but in practice, how can and and laboratory to to pharmaceutical companies, at in the research laboratory can most accelerate into models to is Mr. Cai Lei and Ice-Breaking as the and clinical has increasing in the or of this often on and can and toward the and is not only a scientific but also a challenge that with and or of while must with data and progress and on and the for The at by providing a collaboration has laboratory into the In of and often Rare and an for for example, by and development while requires both to beyond their not only but also market and policy for incentives for rare disease for their must with clinical such as early in the patients must be at the of patient can guide research and offer both and a of than or the of patient like is the not commercial or on this and must and to and information into and while a understanding of risk and investment are also the of of and in of In the our a as both and We with and to expand the research network and genomics, and This the from research to clinical of therapeutic Our by global scientific and and We with both virtual and and and in and in to and with our to be conditions are we to pharmaceutical and delivery and rapid platforms to clinical trials in with In the of translational medicine on a of and and collaboration from to laboratory can truly be translated into clinical policy incentives and technological such as AI-driven drug screening, accelerate Our is to help a translational where innovation, and collaboration to to Our these efforts and that requires more in the of the of and how can we to to rare disease or programs be established in collaboration with that policy and funding for and or Mr. Cai Lei and Ice-Breaking funding for Rare In collaboration with the of China, the of and and and be could and research, while could targeted resources with scientific and specific rare disease This have a of frameworks research and pharmaceutical can research can offer and can This to from to clinical translation. development to rare disease research within and with providing with and for long-term awareness and and and to advances in rare disease research and the of This public awareness and of in public for to in with patients fosters a deeper of while also the of rare disease research to to more to the In a cross-sector long-term incentives, and is key to the of to to rare diseases such as The priorities of philanthropic patient and pharmaceutical companies are not have with and laboratory models to these these could be more the rare disease how rare disease their of comparable to the have in Mr. Cai Lei and Ice-Breaking are a reality in the rare disease and and access to treatment while companies must and long-term This is particularly in rare diseases. Many of these especially by or could in be with technologies such as gene In practice, patients are with effective and companies often lack the to is that for from scientific concept through clinical with than global pharmaceutical like or These companies are by but they on outside through this we new has public awareness of rare diseases while supporting potential more In parallel, we established a laboratory network with leading research and innovative This collaboration in target discovery, drug disease and screening, traditional and clinical translation. The network innovation, and research toward the is our laboratory with research, we have also on public We on such as progress through and such as of to in our These have patients, particularly with and and that their disease can be have also to the and companies a more for collaboration and Our long-term is to the into a model for rare diseases. The beyond limited also weak patient and is is not one like but the small of each rare disease no can the burden awareness is and patients, and more of to The Ice-Breaking has into a global network for also to from early in rare disease Mr. Cai Lei and Ice-Breaking scientific in we the Ice-Breaking and the “Ice-Breaking The Ice-Breaking companies, and that have to research most to the established and by a core is research into for patients, than In parallel, the Ice-Breaking to a new of to engage in and diseases such as disease and disease. The individuals at to and resources that can in rare disease our is to expand the Ice-Breaking into a global platform for scientific We a network where is not limited by but by a to the to worldwide, we to the and and accelerate progress in rare disease In this the is not a of but also a for building an community to for Rare diseases are frequently as can pharmaceutical companies be to this Mr. Cai Lei and Ice-Breaking In to is not to must also can offer This to rare disease drug development. to pharmaceutical companies is the of If orphan drug are may to expand patient access in the but in the for companies to such The is that patients may with no at This is orphan drug are they that innovation is in new therapies drugs are be through such as public health commercial or The of this where combined with enabled both innovation and patient The deeper challenge lies in the of rare disease are and most face a the and of are to the potential development is a and to costs, companies and are to commit At of the of pharmaceutical companies in rare diseases remains within the of than sustainable this rare disease research must be not as an burden but as a This requires frameworks in patients, and to and for sustainable In China, is to both the and the of rare disease while innovative models of and can global pharmaceutical companies rare disease drug development not as but as an and meaningful where scientific innovation and patient are support and challenges are of rare disease such as the of gene access to and models of collaboration are frequently can these be and broader have for and public Mr. Cai Lei and Ice-Breaking is a heterogeneous no patients progress in the same the of patient to the rare disease patient with the same to in an trial disease. that by the a trial no the Despite efforts by companies, and the treatment for in like that of an from the of the scientific progress and patient advances have the therapy to target an a yet of million beyond for most a small RNA therapy with is early in with in only to patients to for approval often a but is way could the has not yet clinical not of only to In the of treatments, many patients are or to interventions through clinical For this an of yet the is often and the the also has a to public The central is how to regulatory while also to the challenges by rare disease but access are to these rare disease drugs have for and more than therapies have on with In while new in for innovative drugs to as as the in for testing and clinical trials have for rare disease both and cost. incentives and have the burden of or orphan and now to of market In the to trial for rare diseases. Despite these the demand for remains particularly for and diseases where therapies offer and gene therapies, have a global in in such In China, their development and face central barrier is that data from be in clinical they must be into trials and the patients can While this also for patients with diseases such as can the access and of offer for with In the are by a of and patient and from flexible ethics and This innovation and that can into development. has a allowing advanced therapies to be in urgent outside market while a of clinical has pioneered for medicine their on early data from while These not but they that patients with diseases for the traditional pace of drug development. Our is of a rare disease research community as an “infinite a of and this requires not only but also and both and the our is progress against rare diseases on a through can we into The of rare disease treatment not be by requires alignment a fragmented For Rare diseases are not but central to personalized offer rapid translational and to platform is is not complexity, but For The from AAV reflects risks, but also a Rare disease pipelines demand new modular adaptive and not traditional and precision long-term For innovation often where market logic translational and are but and flexible must be to this For clinical Rare disease trials not volume. stratification, and through patient like are no they are the For data and ethics are global and patient registries are infrastructure for translational For are no and even trial patient are research to for a care system that treatment, and The model by Mr. Cai and that urgency, and collaboration can accelerate progress where systems For the Rare not Rare diseases how we and scientific rare disease innovation is not is a for how our systems truly and to this the and the and in data and and the of the on of patient and to the on scientific and and the The of the community who care rare diseases, as as the We for to the in this with This by the for the and Research and the Health The no of information is Mr. Cai Lei is the of a patient and research platform in this in this and information to or that could be as a potential of and are the at